Navigation Links
Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Date:2/18/2011

conducted after 468 deaths.

An independent Data and Safety Monitoring Board (DSMB) will assess blinded safety measures and demographics at regular intervals throughout the study or as determined by the DSMB chair. The DSMB will also review interim irPFS data, unblinded at the group level, after 200 irPFS events. At the time of interim sample size review, the DSMB may recommend changes to the sample size or early termination of the study for efficacy or safety reasons as detailed in the protocol.

Key DatesFirst patient recruited Q3 2011

Interim data analysis* Q4 2012 - 1Q 2013

Final data analysis * Q4 2013 - 1Q 2014

*As an event driven study with adaptable design to have the flexibility after interim analysis to adjust patient size and study duration. Precise timelines are driven by these events of study patient progression free survival and/or overall survival and this can only be indicative.

Study SummaryThe purpose of this study is to determine whether CVac™ is effective in the treatment of Patients With Epithelial Ovarian Cancer (EOC) Following Optimal Debulking Surgery and First-line Chemotherapy as assessed by progression free survival or overall survival.

EndpointsPrimary Objectives

  • To assess the efficacy, in terms of immune-related progression-free survival (irPFS), of CVac™ as compared with placebo for maintenance treatment in patients with epithelial ovarian cancer (EOC) following optimal debulking surgery and first-line chemotherapy
  • To assess the efficacy, in terms of overall survival (OS), of CVac as compared with placebo for maintenance treatment in patients with EOC following optimal debulking surgery and first-line chemotherapy.

  • Secondary Objectives

  • To assess the safety and tolerability of CVac™ as compared with placebo
  • To assess health-related quality of life (QoL) related to CVac treatment as compared with plac
    '/>"/>

  • SOURCE Prima BioMed Ltd
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
    2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    3. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
    4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
    5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
    6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
    7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
    8. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
    9. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
    10. Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
    11. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
    (Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
    (Date:1/23/2015)... and BOSTON , January 23, 2015 ... and development company, is delighted to announce that the ... to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for the ...
    Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
    ... at the American Heart Association Scientific Sessions ... ... Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced the successful ... the,company,s innovative and proprietary investigational vaccine being,developed to treat nicotine ...
    ... announced,today that the first patient was enrolled in ... the treatment of herpes zoster, also known as,shingles. ... and bioavailability. "The initiation of this dose-finding ... valomaciclovir," said Fred Volinsky, MD, Chief Executive,Officer. "Shingles, ...
    Cached Medicine Technology:Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles 2
    (Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce ... ever created for kids with cancer. The Chemo Duck App, available ... filled with enjoyable games to help children of all ages living ... helps to keep kids entertained, educated and at ease while waiting ...
    (Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
    (Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
    (Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
    (Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
    Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
    ... to consider the rising health emergencies and crisis in ... have helped// to promote closer regional cooperation. ... attempts for development of sustainable programs for Southeast Asian ... the 8th ASEAN Health Ministers Meeting was the ...
    ... use a protein that has been originally isolated from fish ... modified technology. ,The parent company, Unilever, have claimed ... creams that are of low-calorie, and low fat. They explained ... versions of their best selling products like the Cornetto, Magnum, ...
    ... is because hospitals in England are so overcrowded, says a ... study found that more than three-quarters of hospitals in the ... occupancy rates with a third of the trusts exceeding 81 ... that the high rates mean that there is very less ...
    ... Bibi in Pakistan's North West Frontier Province (NWFP) had never ... to look for buyers. ,It was the only ... husband Izat Gul, 43 - could think of to raise ... ,They struck a deal with a family they ...
    ... In a bid to upgrade tertiary healthcare infrastructure and ... institutions in the country// at a cost of Rs.15.6 ... taken at a meeting of the Cabinet Committee on ... an eye on underserved states like Jammu and Kashmir, ...
    ... US has teamed up with the UN's Children's Fund to ... in seven provinces of China. ,Dubbed as 'Skills ... learning materials for teachers and peer educators to use in ... and other sports equipment to help young people learn about ...
    Cached Medicine News:Health News:Regional Cooperation Promoted in Southeast Asia 2Health News:Wall's To Develop Low-fat Ice-cream Using Fish Blood 2Health News:Impoverished Parents sell their Daughter to Treat their Ailing Kids 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: